Get the Facts on Chronic Pain

40%

Up to 40% of the U.S. population suffers from chronic pain and is often at risk for developing further complications. 1, 2

25%

As many as one in four patients receiving long-term opioid therapy in a primary care setting struggle with opioid addiction. 4

$635 Billion

$635 Billion in annual costs are associated with chronic pain. 3

20 Million

At least 20 million Americans are estimated to have some form of peripheral neuropathy, a key contributor to chronic pain. 5

Our Solution

The Freedom® Peripheral Nerve Stimulator (PNS) and Spinal Cord Stimulator (SCS) Systems involve a minimally invasive, percutaneous procedure that includes an implanted stimulator, external transmitter assembly, and customized therapy for your patients to receive pain relief.
Female wearing a Peripheral Nerve Stimulation wearable on her arm, made by Curonix.

Broad Coverage

Each implanted neurostimulator contains a 4-contact or 8-contact electrode array and a connected receiver. The separate receiver is connected intraoperatively and supplies broad coverage, allowing for flexibility in challenging areas during surgical placement.

Power

High Frequency-Electromagnetic Coupling (HF-EMC) delivers energy from the external transmitter assembly to the implanted neurostimulator. HF-EMC technology provides continuous broad coverage area up to 6cm in depth*, allowing flexible implantation without losing device connectivity.

*Internal testing on file with Curonix.

No Implanted Battery

Powered by an external transmitter assembly giving patients an easy-to-use remote control to power their device on and off without the need for an implanted battery.

Purposefully Designed Wearables

The wearable is customized to fit the Curonix product, providing patients with the freedom to seamlessly return to their daily activities without experiencing loss of connectivity.
Medical Education
Interested in getting in-depth knowledge about our products? View our educational opportunities.
Learn More
Provider Resources
Get access to additional educational content, including videos and more.
Learn More
References:
1
Dahlhamer J, Lucas J, Zelaya C, et.al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults – United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:pg.1
2
Peripheral Neuropathy. National Institute of Neurological Disorders and Stroke. Retrieved from NINDS website: 2023. https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy#
3
U.S. Department of Health and Human Services (2019, May). Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. Retrieved from U. S. Department of Health and Human Services website: https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html
4
U.S. Department of Labor. Risk Factors for Opioid Misuse, Addiction, and Overdose. Retrieved from U. S. Department of Labor website: https://www.dol.gov/agencies/owcp/opioids/riskfactors
5
https://nationalpain.org/fast-facts-about-pain
REC-11-189 REV. 1
Content contained or made available through this website is for informational purposes only, Curonix has no vested interest in any specific physician(s), nor do we provide any recommendation, assurance, or guarantee with respect to their service. This information does not constitute medical, legal, or any other type of professional advice. Curonix LLC is a manufacturer of medical devices and does not practice medicine. Consult a qualified healthcare professional for advice regarding the diagnosis and treatment of any medical condition. Individual results may vary [depending on a variety of patient-specific attributes and related factors]. For product safety information, including information on risks, warnings, and possible adverse side effects please see the Instructions for Use.

The Freedom® PNS System is indicated for treatment of chronic, intractable pain of the peripheral nerve origin. The Freedom PNS System is not indicated for use in the craniofacial region.